Shrinkage estimation in two‐stage adaptive designs with midtrial treatment selection

We consider the problem of estimation in adaptive two-stage designs with selection of a single treatment arm at an interim analysis. It is well known that the standard maximum-likelihood estimator of the selected treatment is biased. We prove that selection bias of the maximum-likelihood estimator is maximal when all treatment effects are equal and the most-promising treatment is selected. Furthermore, we consider shrinkage estimation as a solution for the selection bias problem. We thereby extend previous work of Hwang on Lindley's estimator for single-stage multi-armed trials with four or more treatments and post-trial treatment selection. Following Hwang's ideas, we show that a simple two-stage version of Lindley's estimator has uniformly smaller Bayes risk than the maximum-likelihood estimator when assuming an empirical Bayesian framework with independent normal priors for the group means. For designs that start with two or three treatment groups, we suggest using a two-stage version of the common estimator of the best linear unbiased predicator of the corresponding random effects model. We show by an extensive simulation study that the shrinkage estimators perform well compared with maximum-likelihood and previously suggested bias-adjusted estimators in terms of selection bias and mean squared error.

[1]  W. Brannath,et al.  The advantages and disadvantages of adaptive designs for clinical trials. , 2004, Drug discovery today.

[2]  G. Hommel Adaptive Modifications of Hypotheses After an Interim Analysis , 2001 .

[3]  Nigel Stallard,et al.  Point estimates and confidence regions for sequential trials involving selection , 2005 .

[4]  C. Stein Confidence Sets for the Mean of a Multivariate Normal Distribution , 1962 .

[5]  Harold B. Sackrowitz,et al.  Two stage conditionally unbiased estimators of the selected mean , 1989 .

[6]  John Whitehead,et al.  On the bias of maximum likelihood estimation following a sequential test , 1986 .

[7]  Frank Bretz,et al.  TUTORIAL IN BIOSTATISTICS Adaptive designs for confirmatory clinical trials , 2022 .

[8]  W. Brannath,et al.  Selection and bias—Two hostile brothers , 2009, Statistics in medicine.

[9]  Frank E. Harrell,et al.  Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2001 .

[10]  L Shen,et al.  An improved method of evaluating drug effect in a multiple dose clinical trial , 2001, Statistics in medicine.

[11]  Jack Bowden,et al.  Unbiased Estimation of Selected Treatment Means in Two‐Stage Trials , 2008, Biometrical journal. Biometrische Zeitschrift.

[12]  M Kieser,et al.  Combining different phases in the development of medical treatments within a single trial. , 1999, Statistics in medicine.

[13]  Harold B. Sackrowitz,et al.  A Decision Theory Formulation for Population Selection Followed by Estimating the Mean of the Selected Population , 1988 .

[14]  Tim Friede,et al.  A group‐sequential design for clinical trials with treatment selection , 2008, Statistics in medicine.

[15]  Martin Posch,et al.  Testing and estimation in flexible group sequential designs with adaptive treatment selection , 2005, Statistics in medicine.